- Show all
- Alicaforsen - review papers
- Alicaforsen - treatment case series papers
- Alicaforsen - Phase 2 Data
- Antisense
- Inflammatory Bowel Disease
- ICAM-1
- Renzapride - Irritable Bowel Syndrome Phase 2 Data
- Renzapride - Irritable Bowel Syndrome Phase 3 Data
- Renzapride in Systemic Scleroderma - Overall Disease Pathology
- Renzapride in Systemic Scleroderma - Gastrointestinal Involvement
- Renzapride in Cystic Fibrosis - Gastrointestinal Involvement
- Renzapride in Cystic Fibrosis - Therapeutic Effect of "Prides"
- Renzapride in Gastroparesis Phase 2 Data
Effect of renzapride on transit in constipation-predominant irritable bowel syndrome
Renzapride - Irritable Bowel Syndrome Phase 2 Data
Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, Burton D & Thomforde, G. (2004)
Clin Gastroenterol Hepatol; 2: 895–904
Circulating soluble adhesion molecules in inflammatory bowel disease
Patel, Pall et al
Eur J Gastroenterol Hepatatol 1995 7;11; 1037-1041
Spontaneous aggregation of leukocytes in active ulcerative colitis might be ICAM-1 dependent
Vainer B, Berliner S, Nielsen OH
Inflammation Research Birkhäuser Verlag, Basel, 2004
Ulcerative Colitis
Ingrid Ordas, Lars Eckmann, Mark Talamini, Daniel C Baumgart, William J Sandborn
Lancet 2012; 380: 1606-19
Alicaforsen for the treatment of inflammatory bowel disease
V. Jairath, R. Khanna, B.G. Feagan
Expert Opin Investig Drugs 2017 Jul 6:1-7
An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis
P. Miner JR, M. Wedel, B. Bane & J. Bradley
Aliment Pharmacol Ther (2004) 19: 281-286
A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis
S.J.H. Van Deventer, J.A. Tami, M.K. Wedel, European Colitis Study Group
Gut (2004) 53: 1646-1651
Bioavailability and therapeutic activity of alicaforsen administered as a rectal retention enema to subjects with active ulcerative colitis
P.B. Miner JR, R.S.Geary, J. Matson, E. Chuang, S. Xia, B.F. Baker & M.K. Wedel
Aliment Pharmacol Ther (2006) 23: 1427-1434
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild-to-moderate left-sided ulcerative colitis: a randomised, double-blind, active-controlled trial.
P.B. Miner JR, M.K. Wedel, S. Xia, B.F. Baker
Aliment Pharmacol Ther (2006) 23: 1403-1413
Disclaimer
The information in “published papers” is provided by Atlantic Healthcare plc, and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.